Thermo Fisher Scientific Completes Acquisition of Brammer Bio

Thermo Fisher Scientific Inc., the world leader in serving science, announced that it has completed its previously announced acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, for approximately $1.7 billion in cash.  The completion of the transaction follows the receipt of all required regulatory approvals.

Brammer Bio has nearly 600 employees at primary locations in Massachusetts and Florida and will become part of Thermo Fisher’s Pharma Services business within its Laboratory Products and Services Segment.

Learn more about Thermo Fisher Scientific Completes Acquisition of Brammer Bio.